Efficacy of a Streamlined Heart Failure Optimization Protocol

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-17

Study Completion Date

2024-01-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The SHORT trial compares the current standard optimization protocol to a shortened protocol in a randomized control trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Optimising Congestive Heart Failure Outpatient Clinic Project

NCT01671995

Heart Failure

COMPLETED NA

Cardiovascular Responses in Congestive Heart Failure With Cheyne- Stokes Respiration

NCT00495196

Heart Failure, Congestive Cheyne-Stokes Respiration

COMPLETED NA

A Virtual Heart Failure Optimization Program for Guideline Directed Medical Therapy and Cardiac Rehabilitation

NCT05689086

Heart Failure With Reduced Ejection Fraction

UNKNOWN

Non-invasive Ventilation in Patients With Cardiac Heart Failure

NCT05433610

Heart Failure

COMPLETED NA

Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

NCT06671314

Heart Failure With Reduced Ejection Fraction Heart Failure With Preserved Ejection Fraction

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The SHORT trial compares the current standard optimization protocol to a shortened protocol in a randomized control trial. It assesses whether an accelerated protocol leads to faster optimization and a greater degree of optimization.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure with Reduced Ejection Fraction Chronic Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard Arm

Both the current European Society of Cardiology (ESC) and the National Institute of Health and Care Excellence (NICE) guidelines advise that chronic stable heart failure patients with severely impaired left ventricular systolic function should initially be optimized as follows:

Visit 1: Angiotensin-converting enzyme inhibitor (ACEi)/Angiotensin receptor blocker (ARB) and Low dose Beta blocker commenced Visit 2: ACEi/ARB up-titrated; (Beta Blocker up-titrated) Visit 3: ACEi/ARB up-titrated; (Beta Blocker up-titrated) Visit 4: Mineralocorticoid receptor antagonist (MRA) added Visit 5: MRA up-titrated Visit 6: Switch ACEi/ARB to Entresto 49/51 mg twice daily (BD) Visit 7: Modify Entresto dose to 97/103 mg BD Visit 8: Sodium-glucose cotransporter-2 inhibitor (SGLT2i) started

Group Type ACTIVE_COMPARATOR

Standard Protocol

Intervention Type OTHER

Current standard optimization protocol as per NICE and ESC

Streamlined protocol arm

Patients are optimized according to the accelerated protocol adapted from and based on the principles proposed by Prof McMurray and Prof Packer (Circulation 2021;143:875-877)

Visit 1: Low dose Beta Blocker started, SGLT2i started \& Entresto\* started

\*The starting dose of Entresto will be determined by the baseline blood pressure (BP) (a dose of 24/26 mg twice daily (BD) is to be started if the systolic BP is less than 110 mmHg otherwise a dose of 49/51 mg BD is to be started)

Visit 2: MRA added if renal function and potassium levels permit (Beta Blocker increased if BP and pulse rate permit)

Visit 3: MRA/Entresto up-titrated if BP and renal function and potassium levels permit (Beta Blocker increased if BP and pulse rate permit)

Visit 4+: Beta Blocker increased if BP and pulse rate permit. Further visits may be required to facilitate a gentle up-titration of Beta Blockers.

Group Type EXPERIMENTAL

Streamlined protocol

Intervention Type OTHER

A streamlined drug protocol for optimizing heart failure medication

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Streamlined protocol

A streamlined drug protocol for optimizing heart failure medication

Intervention Type OTHER

Standard Protocol

Current standard optimization protocol as per NICE and ESC

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ejection fraction of less than or equal to 40%
* Increased NT-proBNP level:
* ≥ 600 pg per milliliter or
* ≥400 pg per milliliter if they had been hospitalized for heart failure within the previous 12 months or
* patients with atrial fibrillation or atrial flutter on baseline electrocardiography were required to have an NT-pro BNP level of at least 900 pg per milliliter, regardless of their history of hospitalization for heart failure or
* recent heart failure admission or clinical diagnosis of heart failure.
* Patients who are either naïve to or taking no more than 25% target doses of Beta Blockers or ACEi or ARB before starting the trial.

Exclusion Criteria

* Systolic BP of less than 100 mmHg on 2 consecutive measurements
* Estimated glomerular filtration rate (eGFR) less than 30 ml/min/1.73m2
* Type 1 diabetes mellitus
* Cognitive impairment that in the opinion of the investigator may lead the patient to be unable to understand and/or comply with the study medications, procedures and/or follow-up
* Uncorrected primary valvular disease
* Active malignancy treatment at time of visit 1
* Women of child-bearing potential who are not willing to use a medically accepted method of contraception that is reliable in the judgement of the investigator\*
* Women who are pregnant or breastfeeding
* History of angioedema, or hereditary or idiopathic angioedema
* Severe hepatic impairment, biliary cirrhosis or cholestasis
* Patients who are receiving treatment with an aliskiren-containing product who have diabetes mellitus or renal impairment (eGFR \<60 ml/min/1.73 m2)

* Highly effective methods of contraception include implants, injectables, combined oral contraceptives (the participant must have been on a stable dose for at least 3 months before entering the trial), intrauterine device, vasectomised partner, or true sexual abstinence (when this is the preferred and usual lifestyle of the patient and does not include periodic abstinence \[e.g. calendar, ovulation, symptothermal or post-ovulation methods\]). Use of such methods must be maintained throughout the trial and for 7 days after the end of the trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No